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Introduction: Spondyloarthritis (SpA) comprises a group of diseases often associated with HLA-B27 and characterized
by inflammation of the entheses and joints of the axial skeleton. The inflammatory process in SpA is presumably driven
by innate immune cells but is still poorly understood. Thus, new tools for monitoring and treating inflammation are
needed. The family of CD18 integrins is pivotal in guiding leukocytes to sites of inflammation, and CD18 hypomorphic
mice develop a disease resembling SpA. Previously, we demonstrated that altered soluble CD18 (sCD18) complexes in
the blood and synovial fluid of patients with arthritis have anti-inflammatory functions. Here, we study the mechanisms
for these alterations and their association with SpA disease activity.
Methods: Plasma levels of sCD18 in a study population with 84 patients with SpA and matched healthy controls
were analyzed with a time-resolved immunoflourometric assay (TRIFMA). Binding of sCD18 to endothelial cells and
fibroblast-like synoviocytes (FLSs) was studied with confocal microscopy. Shedding of CD18 from peripheral blood
mononuclear cells (PBMCs) was studied with flow cytometry and TRIFMA.
Results: Plasma levels of sCD18 were decreased in patients with SpA compared with healthy volunteers
(P <0.001), and the lowest levels were in the HLA-B27-positive subgroup (P <0.05). In a multiple regression model,
the sCD18 levels exhibited an inverse correlation with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
(P <0.05), the level of morning stiffness (P <0.05), the Bath Ankylosing Spondilitis Metrology Index (P <0.05), the
physician global assessment score (P <0.01), and the sacroiliac magnetic resonance imaging activity score (P <0.05). The
mechanisms for these changes could be simulated in vitro. First, sCD18 in plasma adhered to inflammation-induced
intercellular adhesion molecule 1 (ICAM-1) on endothelial cells and FLS, indicating increased consumption. Second,
CD18 shedding from SpA PBMCs correlated inversely with the BASDAI (P <0.05), suggesting insufficient generation.
CD18 was shed primarily from intermediate CD14++ CD16+ monocytes, supporting the view that alterations in innate
immunity can regulate the inflammatory processes in SpA.
Conclusions: Taken together, the failure of patients with SpA to maintain adequate sCD18 levels may reflect insufficient
CD18 shedding from monocytes to counterbalance the capture of sCD18 complexes to inflammation-induced ICAM-1.
This could increase the availability of ICAM-1 molecules on the endothelium and in the synovium, facilitating leukocyte
migration to the entheses and joints and aggregating disease activity.* Correspondence: vorup-jensen@microbiology.au.dk
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Spondyloarthritis (SpA) comprises a group of common in-
flammatory musculoskeletal diseases, including ankylosing
spondylitis, psoriatic arthritis, arthritis associated with in-
flammatory bowel disease, reactive arthritis, and undiffer-
entiated SpA. Patients with SpA share the characteristics
of a high frequency of the HLA-B27 allele in the MHC I
loci and disease affecting the entheses and joints of the
axial skeleton [1]. In SpA, disease disability is the sum of
the inflammatory burden and chronic changes. Thus, dis-
tinguishing between inflammatory activity and chronic
problems is critical for choosing a proper clinical interven-
tion [2,3].
The inflammatory process in SpA involves innate im-
mune cells such as macrophages, monocytes, and fibro-
blasts [4]. Monocytes are present in the blood and can be
divided into the three subsets: CD14++ CD16− classic
monocytes, CD14++ CD16+ intermediate monocytes, and
CD14+ CD16++ non-classic monocytes [5]. The intermedi-
ate monocyte subset increases during an infection [6] and
is elevated in RA and SpA [7-9]. Intermediate monocytes
have been described to have both pro-inflammatory and
anti-inflammatory activities [5], and the role of intermedi-
ate monocytes in arthritis is still elusive. Disease activity in
SpA is associated with migration of leukocytes to inflamed
joints and entheses [1]. However, the complexity of the in-
flammatory process in SpA is still poorly understood.
The β2 (CD18) family of integrins includes CD11a/CD18
(LFA-1), CD11b/CD18 (Mac-1 or complement receptor
[CR] 3), CD11c/CD18 (CR4, p150,95), and CD11d/CD18
and is crucial in transendothelial migration by the bind-
ing of CD11a/CD18 to intercellular adhesion molecule
1 (ICAM-1) [10,11]. In arthritis, the increased expres-
sion of ICAM-1 results in the migration of leukocytes
to the joints [12]. Animal studies support a central role
of CD18 in the development of SpA. The mouse PL/J
strain carries the CD18 hypomorphic mutation, which
reduces the expression of CD18 to 2% to 16% of wild-
type levels [13]. These mice develop a skin disease that
closely resembles human psoriasis together with a condi-
tion very similar to psoriatic arthritis dominated by enthe-
sitis [14], and the inflammatory response critically involves
macrophages and T helper 17 (Th17) cells [15,16]. Tumor
necrosis factor-alpha (TNFα) induces endothelial expres-
sion of ICAM-1 as well as activation of integrins for ligand
binding [17]. In this way, the success of biological therapy
with anti-TNFα in the treatment of SpA also indirectly
suggests that the CD18 integrins play a role in human
disease.
Emerging literature [18-21] has identified soluble com-
plexes of CD11/CD18. These complexes bind ICAM-1
[18,19] in a way that competes with the binding of cellular-
expressed CD11/CD18, implying an anti-inflammatory role
[18]. In humans, we found alterations in the soluble CD18(sCD18) plasma concentrations in patients with rheumatoid
arthritis (RA) or SpA whereas patients with osteoarthritis
had no such changes [18]. Shedding of CD18 is increased
by TNFα stimulation [18] and occurs in processes that in-
volve matrix metalloproteinase (MMP)-3 and MMP-9
[22,23]. MMP-3 is the activator of the MMP-9 zymogen
[24], and dysregulation is associated with a wide variety of
autoimmune disorders [25], including RA [26] and SpA
[27]. Recently, comprehensive studies in transgenic animals
showed that leukocyte migration is critically dependent on
efficient CD18 shedding, notably in the case of macro-
phage efflux from zones of inflammation [22]. However,
not much is known about the cellular sources and targets
of sCD18, and the association of sCD18 levels in the blood
with other disease activity parameters has never been
studied in any disease.
We previously demonstrated alterations in sCD18 com-
plexes in the blood and synovial fluid of patients with arth-
ritis and showed that sCD18 binding to ICAM-1 could be
an anti-inflammatory regulatory mechanism in the immune
system. Here, we study the mechanisms for these alter-
ations and their association with SpA disease activity. In
SpA, low sCD18 concentrations were part of an aggravated
disease activity state. The low sCD18 levels seemed to be a
result of a combination of increased capture of sCD11/
CD18 complexes onto ICAM-1 expressed on inflamed tis-
sues and insufficient CD18 shedding from monocytes.
Thus, the resulting increased availability of ICAM-1 mole-
cules on the endothelium and in the synovium could facili-
tate increased leukocyte infiltration in the entheses and
joints and increased disease activity. Hereby, our findings
link regulation of leukocyte infiltration by innate immune
cells with inflammation and disease activity in SpA.
Materials and methods
Study populations
At the time of inclusion, the study population comprised
84 patients with axial SpA according to the European
Spondyloarthropathy Study Group (ESSG) criteria [28,29].
At a follow-up 4 years later, 43 of these patients were ex-
amined again (Table 1). A total of 47 patients met the
modified New York criteria for ankylosing spondylitis at
the time of inclusion [28,29], whereas 37 patients had
non-radiograhic SpA. The study population was clinically
well characterized, and self-assessment scores and clinical
scores comprised physician global assessment visual
analogue scale (VAS), patient pain VAS, patient global
VAS, Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI), Bath Ankylosing Spondylitis Functional Index
(BASFI), Bath Ankylosing Spondilitis Metrology Index
(BASMI), thoracic chest expansion and disease duration at
both baseline and follow-up. The test results included C-
reactive protein (CRP), HLA-B27 status, radiography, and
magnetic resonance imaging (MRI). MRI of the sacroiliac
Table 1 Patient characteristics
Characteristics At time of inclusion At follow-up HCs
(n = 84) (n = 43) (n = 28)
Age in years (mean) 37 (35-39) 41 (38-43) 42.9
Gender, percentage female 58 59 57
Diagnosis, percentage of patients
Ankylosing spondylitis 19 19 -
Psoriatic arthritis 11 12 -
Enteropathic arthritis 4 5 -
Reactive arthritis 15 17 -
Undifferentiated SpA 51 47 -
HLA-B27, percentage positive 60 55 -
Disease duration in years (mean)a 8.0 (7.0-9.0) 12.6 (9.8-15) -
Treatment, percentage of patients
No 67 - -
MTX 8 - -
Salazopyrin 11 - -
Anti-TNFα 7 12 -
Self-assessment scores -
BASDAI, 0-100 (mean) 32 (26-37) 35 (28-42) -
BASFI, 0-100 (mean) 20 (16-25) 22 (16-28) -
Patient pain, 0-100 (mean) 32 (26-38) 33 (26-41) -
Patient global, 0-100 (mean) 32 (26-38) 31 (23-38) -
Level of morning stiffness, 0-100 (mean) 36 (29-43) 36 (27-44) -
Duration of morning stiffness, 0-100 (mean) 33 (26-41) 29 (20-38) -
Clinical scores
BASMI, 0-100 (median) 0 (0-0) 0 (0-10) -
Physician global, 0-100 (mean) 16 (13-20) 20 (16-25) -
Thoracic chest expansion in cm (mean) 4.1 (3.9-4.4) 4.9 (4.5-5.3) -
Test results
CRP in mg/L (median) 2.1 (1.3-3.9) 1.0 (0.5-2.5)
SIJ MRI activity, 0-40 (mean) 7.5 (5.9-9.0) 4.3 (2.9-5.7) -
Spine MRI activity, 0-81 (median) 1 (0-4) 1 (0-2) -
SIJ MRI chronicity, 0-48 (mean) 15 (12-18) 17 (13-22) -
Spine MRI chronicity, 0-207 (median) 0 (0-4) 0 (0-5) -
Numbers in parentheses are 95% confidence interval for measures with a Gaussian distribution and 25% to 75% percentiles for measures with a non-Gaussian
distribution. aDisease duration was defined as duration since start of symptoms. -, not available; Anti-TNF-α, anti-tumor necrosis factor-alpha; BASDAI, Bath
Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondilitis Metrology Index; CRP,
C-reactive protein; HC, healthy control; MRI, magnetic resonance imaging; MTX, methotrexate; SIJ, sacroiliac joint; SpA, spondyloarthritis.
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follow-up and radiography of the SIJ at baseline were in-
cluded in this study (Table 1). A specialist radiologist who
was experienced in SpA but who had no knowledge of the
clinical findings analyzed all MRI and radiographic tests.
The MRI changes were graded by using methods previously
described [30,31]. In summary, the MRI SIJ and spinal ac-
tivity scores were made in accordance with the Danish
methods primarily differing from the SpondyloarthritisResearch Consortium of Canada (SPARCC) methods by
using fully three-dimensional assessment of the SIJ and the
spine [32,33]. The intra- and inter-observer agreements of
the methods have been demonstrated to be acceptable
[30,31].
One SpA patient with peripheral arthritis was included
for growing fibroblast-like synoviocytes (FLSs) from syn-
ovial fluid mononuclear cells (SFMCs). The patient con-
tacted the out-patient clinic because of a knee joint
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sults were recorded.
Plasma from age- and gender-matched healthy controls
(HCs) from either the Blood Donor Bank at Aarhus Uni-
versity Hospital or from patients undergoing orthopedic
surgery at the Department of Orthopaedics at Aarhus Uni-
versity Hospital (n = 28) was included for measuring
sCD18 plasma concentration (Table 1). Peripheral blood
mononuclear cells (PBMCs) from HCs were included for
in vitro studies of spontaneous shedding of CD18 from
PBMCs, T cells, natural killer (NK) cells, and monocytes.
All plasma samples were collected in heparinized tubes
and kept at −80°C until use. PBMCs and SFMCs were iso-
lated by conventional Ficoll-Paque (GE Healthcare, Little
Chalfont, Buckinghamshire, UK) density-gradient centrifu-
gation and cryopreserved at −135°C until time of analysis.
HC PBMCs were isolated from buffy coats for the in vitro
studies of spontaneous shedding of CD18.
Quantification of sCD18 and MMP-9 by time-resolved
immunofluorometric assays
The IgG1 monoclonal antibodies (mAbs) against CD18
were produced by GenScript from the hybridoma cell lines
CRL-2839 (KIM185) and CRL-2838 (KIM127) followed by
protein A/G purification. The mouse IgG1 isotype (cat.
no. M7894; Sigma-Aldrich, St. Louis, MO, USA) was puri-
fied from an ascites suspension with protein A/G purifica-
tion. Biotinylated forms of the antibodies were made by
use of Biotin N-hydroxysuccinimide ester (cat. no. 14405;
Sigma-Aldrich) [18].
Detection of sCD18 in plasma samples and supernatants
from in vitro cell cultures was carried out by time-
resolved immunofluorometric assays (TRIFMAs) by using
a sandwich technique as previously described [18]. Briefly,
microtiter wells (FluoroNunc Maxisorp, 437958; Nunc,
Roskilde, Denmark) were coated with antibody to CD18
(KIM185) or mouse IgG1. The wells were washed in Tris-
buffered saline (TBS)/Tween and blocked by incubation
with 200 μL TBS with 1 mg/mL human serum albumin
for 1 hour at room temperature (RT). After washes, sam-
ples of 100 μL heparinized plasma diluted 1:10 and 1:5 or
supernatants diluted 1:2 in TBS/Tween with 1 mM CaCl2,
1 mM MgCl2, and 100 μg/mL aggregated human Ig were
added to the wells, and the plates were incubated over-
night at 4°C. After incubation of the diluted samples, the
wells were washed and subsequently incubated with
100 μL biotinylated antibody to CD18 (KIM127). After
washing of the wells, Eu3+-conjugated streptavidin was
applied and the signals were read by time-resolved
fluorometry. Signals from patient samples were com-
pared against a standard curve made from titrations of
plasma from an HC.
Detection of MMP-9 was carried out by TRIFMA as
described for the quantification of sCD18 by modifying acommercially available enzyme-linked immunosorbent
assay kit (SEK10327; Sino Biological, Inc., Daxing, China).
An IgG1 mAb to MMP-9 (clone 4A4H5D8) was coated
into microtiter plate wells at a concentration of 2.0 μg/mL.
Samples were diluted in TBS/Tween with CaCl2, MgCl2,
and aggregated human Ig. For detection of captured
MMP-9 antigen, a rabbit mAb to MMP-9 (clone 31) was
diluted to a concentration of 1 μg/mL in TBS/Tween with
100 μg/mL bovine IgG [18]. Signals from the analyzed
samples were compared against a standard curve made
from titrations of the HC plasma also used for sCD18
measurements. As a control, plates coated with murine
IgG1 isotype were prepared and the signals from these
wells were subtracted from the signals recorded in wells
with the mAb to MMP-9.
Confocal microscopy of sCD18 binding to ICAM-1
expressed on EA.hy926 cells and SpA FLSs
The EA.hy926 endothelial cell line was cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% (vol/vol) fetal calf serum (FCS), peni-
cillin, streptomycin, and glutamine. FLSs were grown
from SFMCs as done previously [34]. Briefly, SFMCs
were isolated and cryopreserved as described above. The
cells were thawed and cultured in supplemented DMEM at
a concentration of 2 × 106 cells/mL at 37°C in a humidified
incubator with 5% CO2 (vol/vol) replacing the medium
every 3 to 4 days. When the cell layer was 70% confluent,
the FLSs were passaged by trypsin/ethylenediaminetetra-
acetic acid (EDTA) treatment and used for analyses at pas-
sage 5. Sterile glass slides were placed in 24-well cell
culture plates and aseptically treated with 300 μL of 0.1%
(wt/vol) polylysine dissolved in water (cat. no. P8920;
Sigma-Aldrich) for 5 minutes. After thorough rinsing with
sterile water, the glass slides were allowed to dry for 2 hours.
Either EA.hy926 cells or FLSs were then seeded at a con-
centration of 2.5 × 104 cells/mL in supplemented DMEM
and incubated for 24 hours at 37°C. The cells were either
stimulated with TNFα (cat. no. 300-01A; PeproTech,
Rocky Hill, NJ, USA) at a concentration of 10 ng/mL or
incubated with medium alone for 24 hours at 37°C. After
aspiration of the culture medium, cells were incubated
with 50% (vol/vol) heat-inactivated HC serum with a
known concentration of sCD11/CD18 (542 mU sCD18
per mL) in 150 mM NaCl, 5 mM KCl, 1 mM MgCl2,
1.8 mM CaCl2, 1 mM MnCl2, 10 mM HEPES, pH 7.4
(Binding Buffer). As another source of sCD11/CD18, add-
itional incubations were made with 50% (vol/vol) SFMC
culture supernatant with sCD11/CD18 (approximately
25 mU/mL) in Binding Buffer or Binding Buffer alone for
16 hours at 37°C. Wells were washed twice, and cells were
fixed with 300 μL 3.7% (vol/vol) paraformaldehyde for
10 minutes at RT. Unspecific binding was blocked with
both 10 μg/mL murine IgG and 10 μg/mL bovine IgG in
Kragstrup et al. Arthritis Research & Therapy 2014, 16:R42 Page 5 of 15
http://arthritis-research.com/content/16/1/R42200 μL Binding Buffer for 30 minutes at RT. Cells were
stained with either biotinylated mouse IgG1 anti-CD18
(KIM127) or biotinylated mouse IgG1 isotype in com-
bination with streptavidin Alexa flour 546 (cat. no.
S11225; Invitrogen) or mouse IgG1 anti-ICAM-1 fluor-
escein isothiocyanate (FITC) antibody (clone 6.5B5, cat. no.
F7143; Dako, Glostrup, Denmark). Wells were washed
twice, and glass slides were placed in 2 μL of anti-fade
mounting medium with 1/1,000 4′,6-diamidino-2-pheny-
lindole (DAPI) (cat. no. D9542; Sigma-Aldrich) and allowed
to dry overnight. All micrographs were collected by using a
Zeiss LSM-710 confocal microscope and Pixelmator (Pixel-
mator Team Ltd., Vilinius, Lithuania) for editing.
Flow cytometric analyses of PBMCs
Cells were transferred to FACS tubes (Nunc) and
blocked for unspecific binding in phosphate-buffered
saline with 0.5% (wt/vol) bovine serum albumin (cat. no.
12659; Calbiochem, now part of EMD Biosciences, Inc.,
San Diego, CA, USA), 0.09% (wt/vol) NaN3 together with
10 μg/mL murine IgG and 10 μg/mL bovine IgG (cat. nos.
015-000-003 and 001-000-003; Jackson ImmunoResearch,
West Grove, PA, USA). Cells were stained with either bio-
tinylated mouse IgG1 mAb to CD18 (KIM185) or biotinyl-
ated mouse IgG1 isotypic control in combination with
streptavidin-FITC (Dako). According to the manufac-
turer’s instructions, mouse IgG1 anti-CD163 PE antibody
(clone MAC2-158, cat. no. CD163-158P; Trillium Diag-
nostics), mouse IgG2a anti-CD14 ECD antibody (clone
RMO52, cat. no. PN IM2707U; Beckman Coulter), mouse
IgG1 anti-CD16 APC antibody (clone eBioCB16, cat. no.
17-0168; eBioscience, San Diego, CA, USA), mouse IgG1
anti-CD3 ECD antibody (clone UCHT1, cat. no. A07748;
Immunotech, Beckman Coulter), and mouse IgG2b anti-
CD56 antibody (clone c5.9, cat. no. R7251; Dako) were
used for subanalysis of the PBMCs, and the Live/Dead
staining (cat. no. L10119; Invitrogen) was used for viabil-
ity. All samples were analyzed within 24 hours by using an
FC500 with CXP software (Beckman Coulter) and FlowJo
software version 9.6 (Tree Star Inc., Ashland, OR, USA).
In vitro culture experiments with PBMCs
For in vitro culture experiments with PBMCs, the cells
were thawed and cultured in RPMI medium supple-
mented with 10% (vol/vol) FCS, penicillin, streptomycin,
and glutamine. To study differences in spontaneous CD18
shedding between SpA and HC unfractionated PBMCs,
the cells were incubated at a concentration of 1 × 106
cells/mL. To study differences in spontaneous CD18 shed-
ding from PBMC subsets, T cells (cat. no. 130-091-156;
Miltenyi Biotec, Bergisch Gladbach, Germany), NK cells
(cat. no. 130-092-657; Miltenyi Biotec), and monocytes
(cat. no. 130-091-153; Miltenyi Biotec) were isolated by
negative selection in accordance with the instructions ofthe manufacturer and incubated at a concentration of 1 ×
106 cells/mL. In all PBMC experiments, cells were cul-
tured for 48 hours at 37°C in a humidified incubator 5%
(vol/vol) CO2 without changing of medium. After incuba-
tion, supernatants were stored frozen at −80°C for later
sCD18 analysis with TRIFMA.
Statistical analyses
Gaussian distributed measures were presented by the
mean value, whereas measures with a non-Gaussian distri-
bution were presented by the median value as indicated.
Prior to analyses for statistical significance, the plasma
sCD18 levels were log-transformed. Comparisons of the
plasma sCD18 levels between groups of unpaired and
paired samples were made by using the Student t test in
the unpaired and paired modes, respectively. Correlation
analyses between disease activity parameters and the
plasma sCD18 levels were performed with the Pearson
correlation for measures with a Gaussian distribution and
with the Spearman correlation for measures with a non-
Gaussian distribution. Multiple regression models were
made with the plasma sCD18 levels and disease activity
parameters correcting for age, disease duration, HLA-B27
status, and treatment at time of inclusion. The same ana-
lyses were made after additional correction for CRP. All cell
culture experiments were analyzed with non-parametric
statistics. The Mann-Whitney U test was used for unpaired
comparisons, the Wilcoxon signed rank test was used for
paired data, and the Spearman correlation was used for as-
sociation studies. A two-tailed P value below 0.05 was con-
sidered significant. Calculations and graphs were made
with Stata version 11.1 (StataCorp LP, College Station, TX,
USA) and GraphPad Prism version 5 (GraphPad Software,
San Diego, CA, USA).
Approval of studies using human samples
All SpA samples were collected in the out-patient clinic in
Aarhus University Hospital or in the Aarhus Rheumatol-
ogy Clinic private practice. All samples were obtained after
informed written consent according to the Declaration of
Helsinki and approved by the Research Ethics Committees
of Central Jutland (project numbers 20050046 and
20058432) and the Danish Data Protection Agency.
Results
The plasma level of sCD18 was lower in SpA patients
compared with healthy controls
We measured the concentration of sCD18 in plasma sam-
ples from patients with SpA and HCs by using TRIFMA.
The levels of sCD18 in plasma from patients with SpA at
both time of inclusion and 4-year follow-up were signifi-
cantly lower than in plasma from HCs (Figure 1). Further-
more, the levels of sCD18 showed a clear overlap between
the three groups. There was no significant difference
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Figure 1 Plasma concentrations of soluble CD18 (sCD18) in
patients with spondyloarthritis (SpA) at the time of inclusion
and at the 4-year follow-up and healthy controls (HCs). The
median values of plasma sCD18 were 639.7 mU/mL (interquartile
range 514.3-726.8 mU/mL) for patients with SpA at the time of
inclusion, 606.1 mU/mL (interquartile range 458.4-691.5 mU/mL) for
patients with SpA at the 4-year follow-up, and 767.2 mU/mL
(interquartile range 628.1-839.7 mU/mL) for HCs. Bars indicate
median and interquartile range. ***P <0.001, ****P <0.0001.
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time of inclusion compared with the second time-point
4 years later (P = 0.10) (Figure 1). No associations were ob-
served between gender or age and plasma sCD18 levels
for either patients with SpA or HCs.
The plasma level of sCD18 was negatively associated with
disease activity and decreased in HLA-B27-positive SpA
We correlated the sCD18 concentration with several dis-
ease activity parameters to analyze for an association be-
tween decrease in sCD18 plasma level and disease activity.
These included scores calculated from information pro-
vided by the patients (BASDAI, BASFI, patient pain VAS,
patient global assessment score, and morning stiffness),
scores resulting from clinical examination (BASMI, phys-
ician global assessment score, and thoracic chest expan-
sion), and objective measures (CRP, sacroiliac joint [SIJ]
MRI activity score, and spine MRI activity score).Significant negative correlations were observed between
the plasma sCD18 levels and BASMI (r = −0.25, P <0.05),
physician global assessment score (r = −0.34, P <0.01), CRP
(r = −0.34, P <0.01), and SIJ MRI activity score (r = −0.25,
P <0.05). No correlations were observed between sCD18
and MRI chronicity scores.
The association of sCD18 plasma level and disease activ-
ity was further investigated by using subgroup and multi-
variate analyses. Overall, the levels of sCD18 in plasma
from HLA-B27-positive SpA patients were reduced com-
pared with HLA-B27-negative SpA patients (Figure 2A).
No differences in plasma sCD18 levels were observed when
comparing the SpA subtypes (ankylosing spondylitis, psori-
atic arthritis, enteropathic arthritis, reactive arthritis, and
undifferentiated SpA), when comparing patients fulfilling
or not fulfilling the modified New York criteria for ankylos-
ing spondylitis, or when comparing patients treated or not
treated with a TNFα inhibitor. Because HLA-B27 positivity
adds to the strength of the SpA diagnosis and because we
found an association between the sCD18 plasma concentra-
tion and HLA-B27 positivity, the HLA-B27-positive SpA
patients were analyzed separately. In this subgroup, signifi-
cant negative correlations were present between the
plasma sCD18 levels and BASDAI (r = −0.39), BASMI
(r = −0.38), level of morning stiffness (r = −0.43), duration
of morning stiffness (r = −0.33), physician global assess-
ment score (r = −0.62), CRP (r = −0.38), and SIJ MRI activ-
ity score (r = −0.35) while thoracic chest expansion
showed a positive association to the plasma sCD18 level
(r = 0.37) (Figure 2B and C).
The association between plasma sCD18 levels and
markers of disease activity was also tested in regression
models with correction for age, disease duration, HLA-B27
status, and treatment at time of inclusion. In these models,
significant negative correlations were observed between the
plasma sCD18 levels and BASDAI, level of morning stiff-
ness, physician global assessment score, BASMI, and SIJ
MRI activity score (Tables 2 and 3). Furthermore, we ana-
lyzed these associations after correcting for CRP to evaluate
whether sCD18 adds to the information already achieved
by the CRP. The associations remained significant for BAS-
DAI, level of morning stiffness, BASMI, and physician glo-
bal assessment score (Additional file 1: Table S1 and
Additional file 2: Table S2). The same tendencies were seen
between plasma sCD18 and markers of disease activity at
4-year follow-up, but these were not significant (data not
shown).
The value of sCD18 plasma concentration as a prognos-
tic marker in SpA was tested by correlating the plasma
sCD18 concentration at baseline with disease activity
scores at the 4-year follow-up (BASDAI, BASFI, patient
pain VAS, patient global assessment score, morning stiff-
ness, BASMI, physician global assessment score, thoracic
chest expansion, CRP, SIJ MRI activity score, and spine
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Figure 2 The soluble CD18 (sCD18) plasma concentration, HLA genotype, and spondyloarthritis (SpA) disease activity. (A) The sCD18
plasma level in HLA-B27-positive versus HLA-B27-negative SpA patients at the time of inclusion. The median values were 605.7 mU/mL (interquartile
range 461.6-704.1 mU/mL) for HLA-B27-positive SpA patients and 670.0 mU/mL (interquartile range 591.8-760.1 mU/mL) for HLA-B27-negative SpA
patients. Bars indicate median and interquartile range. (B) Correlation between the sCD18 plasma levels in HLA-B27-positive SpA patients and
self-assessment and clinical scores. (C) Correlation between the sCD18 plasma levels in HLA-B27-positive SpA patients and clinical test results. Solid lines
represent the best fit in linear regression. *P <0.05; **P <0.01; ***P <0.001; ****P <0.0001.
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http://arthritis-research.com/content/16/1/R42MRI activity score) and changes in these parameters from
the inclusion to the 4-year follow-up. When the entire
group of SpA patients was examined, there were no sig-
nificant associations. When only the HLA-B27-positive
SpA patients were examined, there was a significant nega-
tive correlation between the plasma sCD18 levels at time
of inclusion and disease activity at 4-year follow-up mea-
sured by BASDAI (r = −0.42, P <0.05).
sCD11/CD18 complexes were captured by ICAM-1 on EA.
hy926 cells and SpA FLSs
To provide a rationale for the negative relation between
plasma sCD18 levels and disease activity, the ability ofTable 2 Associations at time of inclusion between plasma sol
self-assessment scores after correction for age, disease durat
BASDAI BASFI Patient pain Patient g
sCD18 ra −0.29 −0.083 −0.14 −0.1
P 0.026 0.54 0.30 0.42
Bold numbers indicate significant correlations. aPartial correlation coefficients. BASD
Spondylitis Functional Index; sCD18, soluble CD18.sCD18 to bind inflammation-induced ICAM-1 was stud-
ied as outlined in the illustration (Figure 3A). First, cells
were stimulated with TNFα to increase the ICAM-1 ex-
pression in the membrane. Second, incubations were
made with sCD18. Third, the cells were stained for cap-
tured sCD18.
A clear signal for sCD18 capture was obtained when
staining the endothelial cell line EA.hy926 after stimula-
tion of the cells with TNFα and incubation with normal
human serum (NHS) as the sCD18 source (Figure 3B). In
the absence of TNFα stimulation, no staining was ob-
served (Figure 3C). As further controls, the cells were in-
cubated with medium without sCD18 or stained withuble CD18 levels in all spondyloarthritis patients and
ion, HLA-B27 status, and treatment
lobal Morning stiffness, level Morning stiffness, duration
1 −0.27 −0.15
0.042 0.26
AI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing
Table 3 Associations at time of inclusion between plasma soluble CD18 levels in all spondyloarthritis patients and
clinical scores and test results after correction for age, disease duration, HLA-B27 status, and treatment.
BASMI Physician global Thoracic chest expansion CRP SIJ activity Spine activity
sCD18 ra −0.030 −0.42 0.12 −0.23 −0.27 −0.068
P 0.015 0.001 0.34 0.069 0.032 0.59
Bold numbers indicate significant associations. aPartial correlation coefficients. BASMI, Bath Ankylosing Spondilitis Metrology Index; CRP, C-reactive protein; sCD18,
soluble CD18; SIJ, sacroiliac joint.
Figure 3 Confocal microscopy analysis of the ability of sCD11/CD18 complexes to bind intercellular adhesion molecule 1 (ICAM-1)
expressed on the human umbilical vein cell line EA.hy926. (A) Illustration of the cellular incubations. In step 1, adherent cells were stimulated
with 10 ng/mL tumor necrosis factor-alpha (TNFα), which increased the ICAM-1 expression. In step 2, a source of CD11/CD18 was added (that is,
either normal human serum (NHS) or supernatant from synovial fluid mononuclear cell culture). In step 3, biotinylated antibody recognizing
ligand-binding activated CD11/CD18 (KIM127) was added followed by addition of fluorochrom-labelled streptavidin for detection using confocal
microscopy. Binding of sCD18 to ICAM-1 expressed on EA.hy926 cells incubated with (B) or without (C) TNFα. Red staining indicates the binding
of sCD18, further indicated with white arrows. The positions of cell nuclei were located by 4′,6-diamidino-2-phenylindole (DAPI) staining, indicated
in blue. The staining was distinctly localized to small foci on the cell membrane on 10% to 15% of the cells. Expression of ICAM-1 on EA.hy926
cells incubated with (D) or without (E) TNFα. ICAM-1 is indicated with a green staining, and cell nuclei are indicated with a blue staining.
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http://arthritis-research.com/content/16/1/R42isotype mouse IgG1. In these conditions, no staining was
seen confirming the CD18 specificity of the KIM127 anti-
body in our experiments (Additional file 3: Figure S1).
Similar findings were made when using primary SpA FLS
and when using SFMC supernatant as sCD18 provider
(Additional file 3: Figure S1).
The cells presented an uneven pattern of ICAM-1 ex-
pression across the cell membrane (Figure 3D) similar to
observations made by Carman and colleagues on human
umbilical vein endothelial cells [35,36]. The strong ICAM-
1 expression was not found in the absence of TNFα treat-
ment (Figure 3E), suggesting that such strong expression
was required for sCD18 capture. ICAM-1 foci with a par-
ticularly strong staining was found on the perimeter of the
cell as judged from the distance (approximately 16-20 μm)
to the cell nucleus (Figure 3D). The distribution of CD18
staining on EA.hy 926 cells showed a similar staining pat-
tern (Figure 3B). We examined the capture of sCD18 from
the supernatants quantitatively to evaluate whether this
weak and distinct staining could be explained by stochio-
metric shortage of sCD11/CD18. Supernatants containing
50% (vol/vol) NHS or 50% (vol/vol) SFMC supernatant
were harvested after 16 hours of incubation with cells pre-
treated either with TNFα or without such treatment. Only
a small reduction in the sCD18 concentration of the super-
natants was found after the cellular incubation, suggesting
that the highly localized staining was not explained by sto-
chiometric shortage of sCD11/CD18 (Additional file 4:
Figure S2).
CD18 shedding from PBMCs was affected by donor
disease activity
To further analyze the negative relation between plasma
sCD18 levels and disease activity, the CD18 shedding
was studied in cultures with PBMCs derived from pa-
tients with SpA or HCs. In a simple comparison, the
spontaneous shedding of CD18 from PBMCs derived
from patients with SpA was increased compared with
cultures of PBMCs from HCs (P <0.01). In subgroup
analysis, the spontaneous shedding of CD18 from
PBMCs derived from HLA-B27-negative SpA patients
was increased compared with cultures of PBMCs from
HCs (Figure 4A), but there were no differences between
HLA-B27-positive SpA patients and HCs (P = 0.69) or
between HLA-B27-negative SpA patients and HLA-
B27-positive SpA patients (P = 0.09).
To clarify whether shedding of CD18 relates to dis-
ease activity in SpA, we correlated shedding of CD18
from SpA patient-derived PBMCs with disease activity
scores. The sCD18 concentrations in SpA PBMC super-
natants correlated negatively with the BASDAI score
(Figure 4B; r = −0.71, P <0.05). A similar trend of nega-
tive correlation with the sCD18 plasma concentration
was found for the other disease scores recorded in thisstudy (data not shown). Since CD18 is a substrate for
MMP-9, we measured the concentration of MMP-9 in the
same PBMC supernatants. In this case, the analysis pre-
sented a non-significant tendency of increasing sCD18
levels with increasing MMP-9 in supernatant from SpA
PBMCs (Figure 4C; r = 0.58, P = 0.08). Taken together,
these data suggest that insufficient generation of sCD18 in
SpA could be part of an increased disease activity.
CD18 was shed primarily from monocytes
To more clearly identify the cellular sources of sCD18, the
cell membrane expression and in vitro shedding were stud-
ied with HC- and SpA-derived PBMCs. For both HC- and
SpA-derived PBMCs, the cell surface expression of CD18
was higher on monocytes compared with both T cells and
NK cells as judged from the median fluorescence intensity
(MFI). NK cells also showed a higher cell surface expression
of CD18 compared with T cells (Figure 5A and B). The
MFIs of the isotype control IgG1 staining were 0.406,
0.414, and 2.46 for T cells, NK cells, and monocytes, re-
spectively. To study the capacity for shedding by these sub-
sets, the cells were separated by application of antibodies to
the canonical markers CD14, CD3, or CD56 of monocytes,
T cells, and NK cells, respectively. The median percentages
of CD14+ cells were 84.3% (interquartile range 82.8%-
89.8%) in the isolated monocytes, 97.5% (interquartile range
96.6%-97.7%) of CD3+ cells in the isolated T cells, and
85.9% (interquartile range 84.1%-90.7%) of CD56+ cells in
the isolated NK cells. As expected from the high CD18 cell
surface expression, supernatants from monocyte cultures
contained a higher sCD18 concentration than supernatants
from both T cells and NK cells (Figure 5C).
Since monocytes had the highest CD18 cell membrane
expression and showed the highest degree of CD18 shed-
ding, we studied the monocyte subpopulations in further
detail. Based on past investigations, the CD14+ cells were
stratified into subsets of classic, intermediate, and non-
classic monocytes by additional staining for cell mem-
brane expression of CD16. The expression of CD18 was
greater on CD14++ CD16+ (intermediate) monocytes com-
pared with both CD14+ CD16+ (non-classic) monocytes
and CD14++ CD16− (classic) monocytes and was greater
on non-classic monocytes compared with classic mono-
cytes (Figure 6A and B). The CD14+ cells were also add-
itionally stained for cell membrane expression of CD163.
The expression of CD18 was stronger on CD163+ than
CD163− monocytes (P <0.001). Confirming the finding
from previous studies of arthritis [7-9], there were a non-
significant, greater proportion of intermediate monocytes
among all monocytes in HLA-B27-negative SpA patients
compared with HCs (Figure 6C). A positive correlation was
observed between the proportion of non-classic (Figure 7A)
and intermediate (Figure 7B) monocytes among all CD14+
monocytes and the concentration of sCD18 in the PBMC
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Figure 4 Spontaneous shedding of CD18 from peripheral blood mononuclear cells (PBMCs) cultured in vitro. (A) Levels of spontaneous
shedding of CD18 from spondyloarthritis (SpA) and healthy control (HC) PBMCs. The median values were 22.0 mU/mL (interquartile range
14.0-51.8 mU/mL) for HLA-B27-positive SpA patients, 51.7 mU/mL (interquartile range 21.5-57.0 mU/mL) for HLA-B27-negative SpA patients,
and 11.2 mU/mL (interquartile range 8.59-12.3 mU/mL) for HCs. PBMCs from 5 HLA-B27-positive SpA patients, 5 HLA-B27-negative patients, and
5 HCs were used. Bars indicate median and interquartile range. (B) Correlation between PBMC donor BASDAI score and the spontaneously shed
CD18 in the PBMC culture supernatant. (C) CD18 spontaneous shedding capacity and correlation with matrix metalloproteinase-9 (MMP-9)
production. PBMCs from 10 patients with SpA were used. Hatched horizontal lines connect identical measurements of sCD18. Solid black lines
represent the best fit in linear regression. *P <0.05.
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Figure 5 Cellular-expressed and shed CD18 attributed to peripheral blood mononuclear cell (PBMC) source. (A) The cell membrane
expression of CD18 on T cells, natural killer (NK) cells, and monocytes using PBMCs from a representative healthy control (HC) with the gating
strategy indicated. (B) The cell membrane expression of CD18 on T cells, NK cells, and monocytes using PBMCs from 10 HCs and 2 patients with
spondyloarthritis (SpA). Levels of CD18 expression were measured by the median fluorescence intensity (MFI). Bars indicate median and
interquartile range. (C) The concentration of sCD18 in supernatants from cultured T cells, NK cells, and monocytes derived from PBMCs from 5
HCs. Bars indicate median and interquartile range. ***P <0.001.
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Figure 6 CD18 expression and distribution of monocyte subsets in healthy controls (HCs) and patients with spondyloarthritis (SpA). (A)
The cell membrane expression of CD18 on CD14+ CD16++ (non-classic) monocytes, CD14++ CD16+ (intermediate) monocytes, and CD14++ CD16−
(classic) monocytes using peripheral blood mononuclear cells (PBMCs) from a representative HC with the gating strategy indicated. (B) The cell
membrane expression of CD18 on non-classic monocytes, intermediate monocytes, and classic monocytes in PBMCs from 5 HCs and 10 patients with
SpA. Bars indicate median and interquartile range. (C) The percentages of intermediate monocytes among all CD14+ monocytes in HLA-B27-positive
SpA, HLA-B27-negative SpA, and HCs. PBMCs from the same 10 patients with SpA and 5 HCs were used. Bars indicate median and interquartile range.
*P <0.05; **P <0.01; ****P <0.0001.
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http://arthritis-research.com/content/16/1/R42culture supernatants, whereas a negative correlation was
found for the proportion of classic monocytes (Figure 7C).
Discussion
The inflammatory process in SpA is still poorly elucidated,
resulting in difficulties in monitoring disease activity and
choosing treatment strategy. Several investigations in ex-
perimental animal models already indicate a central role
of CD18 integrins in SpA-like disease [14-16,37]. We pre-
viously demonstrated alterations in the sCD18 complexes
in the blood and synovial fluid of patients with arthritis
and the ability of sCD18 to inhibit leukocyte binding to
ICAM-1. This study proposes sCD18 as a novel player in
SpA disease pathogenesis. The sCD18 plasma level was
decreased in patients with SpA compared with HCs, and
levels correlated inversely with SpA disease activity scores.
The failure of patients with SpA to maintain normal
sCD18 levels seems to reflect insufficient CD18 shedding
from monocytes to counterbalance the capture of sCD18
complexes to inflammation-induced ICAM-1. In this way,
our findings on sCD18 link increased leukocyte infiltration
potential with disease activity in SpA.
As noted by Feldmann and colleagues [38], inflamma-
tion is regulated by the balance between pro- and anti-inflammatory mechanisms. In this sense, the inflammatory
response may originate as a consequence of over-activity
of pro-inflammatory mechanisms or mechanistic failures
in anti-inflammatory responses. Previously, it was rather
speculative to assign the production of sCD18 to either
one of the two modes of regulating the inflammatory re-
sponse. Yet the ability of sCD11/CD18 complexes to com-
pete with cellular-expressed CD11a/CD18 in ICAM-1
binding [18] indicates that the soluble complexes may aid
in resolving cellular adhesion and hence the formation of
inflammatory foci. We now found at least two indications
to support such anti-inflammatory functions of sCD11/
CD18.
First, we demonstrated the ability of the sCD11/CD18
complexes to bind ICAM-1 in the cell membrane of a hu-
man umbilical vein cell line and primary FLSs established
from a site of major inflammation in SpA. ICAM-1 ex-
pression is increased on the lining and sublining cells of
the synovium and on adjacent endothelial cells in patients
with SpA and is regulated by TNFα [39,40]. Our immuno-
cytological staining for ICAM-1 showed a speckled pat-
tern very similar to previous findings [35,36]. Carman and
colleagues [35,36] revealed that the origin of this morph-
ology is caused at least partly by the formation of ICAM-
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Figure 7 Correlation between monocyte subsets and soluble CD18
(sCD18) in the peripheral blood mononuclear cell (PBMC) culture
supernatant. The percentage of non-classic (A), intermediate (B), or
classic (C) monocytes among all monocytes in a sample of PBMCs
was correlated against the sCD18 concentration in supernatant from
culture of the PBMCs. Samples were analyzed from PBMCs derived
from a total of 5 healthy controls (HCs) and 10 patients with
spondyloarthritis (SpA).
Kragstrup et al. Arthritis Research & Therapy 2014, 16:R42 Page 12 of 15
http://arthritis-research.com/content/16/1/R421-enriched cell membrane protrusions. These protru-
sions are critical in the pro-active role of the endothe-
lium in the transmigration of leukocytes [35,36]. The
deposition of sCD11/CD18 complexes on the cells in-
vestigated in our experiment was not uniform and ap-
peared in a way that could well reflect the selective
binding to such ICAM-1-enriched zones. Indeed, the de-
position was critically dependent on TNFα treatment of
the cells, increasing the ICAM-1 expression. The require-
ment of a dense expression of ICAM-1 is furthermoreconsistent with the biochemical evidence reported earlier
[18] that multimers of sCD11/CD18 (for example, 2 ×
CD11/CD18 and 4 ×CD11/CD18) participate in a polyva-
lent interaction with ICAM-1 molecules, enabling a high
avidity in the interaction [18,41]. In this way, our findings
support that sCD11/CD18 selectively binds ICAM-1-rich
features important for the interaction of leukocytes with the
synovial lining and endothelium of blood vessels. Likewise,
the clinical investigations made in our study suggest that in-
sufficient saturation of these features with sCD11/CD18
captured from the plasma pool may aggravate inflamma-
tion, probably by permitting undue leukocyte adhesion.
Second, it is an important observation that the negative
correlation between the decreased plasma level of sCD18
and disease activity in SpA could be simulated in cell cul-
tures in vitro. Thus, CD18 shedding from SpA patient-
derived PBMCs correlated negatively with the BASDAI
score. This indicates that inflammation may be downregu-
lated by the ability of leukocytes to deliver an elevated pro-
duction of sCD18. In contrast, failure by the leukocytes to
compensate the capture of sCD11/CD18 onto ICAM-1-
expressing surfaces appears to augment inflammation.
Taken together, these data also indicate that a compound
resembling sCD18 could be beneficial as a therapeutic
drug in SpA.
Our investigations identified monocytes as the predomin-
ant contributors to CD18 shedding among PBMCs in cul-
tures in vitro. It is well established that the monocyte
population can be separated into subsets with distinct regu-
latory capabilities [5,42,43]. Intermediate monocytes have
both pro-inflammatory and anti-inflammatory functions.
Thus, they are precursors of osteoclasts in psoriatic arthritis
[7] and promote the expansion of the Th17 subset in RA
[8]. However, intermediate monocytes also show the highest
expression of the anti-inflammatory cytokine IL-10 and are
tolerant to stimulation during infection [6,44]. Also, lack of
CD16+ monocytes may be related to auto-inflammatory dis-
ease [45]. In line with previous studies, we found a high ex-
pression of CD18 integrins in the membrane of monocytes
and especially the intermediate monocyte subset [46,47].
Furthermore, the concentration of sCD18 in PBMC super-
natants correlated with the percentage of intermediate
monocytes among all monocytes. This suggests that inter-
mediate monocytes are the primary producers of sCD18 in
the PBMC subset. In this way, our study proposes a novel
role for intermediate monocytes in the blood as regulators
of leukocyte migration. In SpA this regulatory role seems to
be inadequate. Thus, in HLA B27-negative SpA only, the
percentage of intermediate monocytes among all mono-
cytes was increased, resulting in sufficient upregulation of
CD18 shedding and low disease activity. However, this in-
crease in intermediate monocytes was not seen in HLA
B27-positive SpA, resulting in insufficient CD18 shedding
and higher disease activity.
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sCD18 in patients with SpA and HCs implies that measur-
ing sCD18 will not be of particular value in the diagnosis
of SpA. However, measuring sCD18 could assist in dis-
criminating between inflammatory activity and broader
problems due to chronic changes in SpA. From a clinical
viewpoint, discrimination between ongoing inflammation
and chronicity is thus critical for choosing the proper clin-
ical intervention [2]. To best measure the level of inflam-
mation, many composite scores, such as the BASDAI,
BASFI, and physician global assessment score, have been
developed. However, these measures are only moderately
objective and are difficult to compare across individuals.
Also, BASDAI does not correlate well with objective mea-
sures such as CRP and MRI findings or erythrocyte sedi-
mentation rate [48]. Nevertheless, in lieu of better
measures of disease activity, the BASDAI is currently
regarded as the gold standard regarding treatment initi-
ation and response [49]. This underlines the need for bet-
ter objective measures, especially because the role of CRP
in SpA is debatable, as it is induced mainly by IL-6 and
anti-IL-6 has little effect in SpA [50,51]. In agreement,
CRP showed no correlations with self-assessment scores,
clinical findings, or MRI activity scores in our study popula-
tion (data not shown). By contrast, the decrease in plasma
levels of sCD18 found here correlated with a number of
single and composite inflammatory measures, including
BASDAI, level of morning stiffness, and physician global as-
sessment score and the objective measures BASMI and SIJ
MRI activity score in patients with SpA. These associations
were greater when adjusting for differences in age, disease
duration, HLA-B27 status, and treatment at time of inclu-
sion, making the study population more homogeneous.
Additionally, no correlation was observed between
sCD18 and MRI chronicity scores or patient global
score. Although MRI is not considered the best measure
of structural damage, the MRI chronicity scores used in
this study were based on MRI features described previ-
ously to correlate with radiographic changes [30,31].
Thus, this adds to the validity of sCD18 as a marker of
the inflammatory component of SpA disability. Import-
antly, the association with disease activity remained
after correction for CRP.
Recently, the serum concentrations of both MMP-3 and
MMP-9 have been found to be associated with disease ac-
tivity in ankylosing spondylitis [52,53]. Shedding of CD18
occurs in processes that involve MMP-3 and MMP-9
[22,23]. With the observation that CD18 is a substrate for
MMP-9 [23], measurement on sCD18 may provide an in-
dication of enzymatic activity in vivo, which is central to
pathogenic mechanisms of these diseases [25]. In this way,
sCD18 could be a novel mechanistic biomarker of SpA
disease activity involved in the disease pathogenesis and
reflecting inflammatory processes [54,55].No inflammatory disease controls were assessed in this
study. Thus, the specificity of our findings in SpA is uncer-
tain. Interestingly though, the plasma levels of sCD18 were
decreased in plasma from HLA-B27-positive SpA patients
compared with HLA-B27-negative patients. Additionally,
shedding of CD18 from PBMCs was increased among
HLA-B27-negative patients only. HLA-B27 positivity in
patients with ankylosing spondylitis predicts a poorer
prognosis and a better response to anti-TNFα treatment
[56]. It is unclear whether this reflects a different patho-
genesis in HLA-B27-positive versus HLA-B27-negative
SpA. HLA-B27-positive SpA patients also had increased
BASMI, CRP, and MRI activity scores compared with
HLA-B27-negative SpA patients in our study population
(data not shown). From the established correlations, the
decreased levels of sCD18 in HLA-B27-positive SpA may
thus be explained by the higher degree of disease activity
in this group. However, mechanistic couplings between
HLA-B27 and shedding of CD18 cannot be excluded.
Validation studies are needed to clarify whether measuring
the sCD18 plasma level can be used as a marker of inflam-
matory activity in SpA.Conclusions
The clinical impact of CD18 deficiency has been long
known from the several types of leukocyte adhesion de-
ficiencies [57]. Our work now argues that more subtle
changes in CD18 functions are sufficient to affect dis-
ease activity in SpA through alterations in the systemic
concentration of sCD18. The influences appear to in-
volve the failure of monocyte subsets to maintain a suffi-
cient concentration of sCD11/CD18 complexes. Our work
suggests that a delicate balance exists between cellular-
expressed and sCD18 integrins, which may be disturbed by
the well-characterized changes in MMP activity and
ICAM-1 expression associated with a vast range of illnesses
involving chronic inflammation. With the central role
of CD18 integrins in supporting leukocyte migration and
immunological synapse formation, it encourages the hy-
pothesis that such disturbances are involved in the disease-
causing mechanisms in SpA. This points to the level of
sCD18 as a potential marker of inflammatory activity or a
compound resembling sCD18 as a therapeutic drug.
Additional files
Additional file 1: Table S1. Associations at time of inclusion between
plasma soluble CD18 (sCD18) levels in all patients with spondyloarthritis
(SpA) and self-assessment scores after correction for age, disease duration,
HLA-B27 status, treatment, and C-reactive protein (CRP).
Additional file 2: Table S2. Associations at time of inclusion between
plasma soluble CD18 (sCD18) levels in all patients with spondyloarthritis
(SpA) and clinical scores and test results after correction for age, disease
duration, HLA-B27 status, treatment, and C-reactive protein (CRP).
Kragstrup et al. Arthritis Research & Therapy 2014, 16:R42 Page 14 of 15
http://arthritis-research.com/content/16/1/R42Additional file 3: Figure S1. Confocal microscopy analysis of the ability
of sCD11/CD18 complexes to bind intercellular adhesion molecule 1 (ICAM-
1) expressed on the human umbilical vein cell line EA.hy926 or
spondyloarthritis (SpA) fibroblast-like synoviocytes (FLSs). (A) Schematic of
the cellular incubations. In step 1, adherent cells were incubated with
10 ng/mL tumor necrosis factor-alpha (TNFα), which increased the ICAM-1
expression. In step 2, a source of CD11/CD18 was added (that is, either NHS
or supernatant from peripheral blood mononuclear cell (PBMC) culture). In
step 3, biotinylated antibody recognizing ligand-binding activated CD11/
CD18 (KIM127) was added followed by addition of fluorochrom-labelled
streptavidin for detection with confocal microscopy. (B) Binding of soluble
CD18 (sCD18) to TNFα-treated cells. As outlined above, in step 1, cells were
treated with either TNFα or plain medium as a control. In step 2, either NHS
or culture supernatant was used or plain medium was used as a control. In
step 3, either the antibody to CD18 (KIM127) was used or biotinylated
monoclonal IgG1 immunoglobulin was used as a control. Red staining
indicated the binding of CD18, further indicated with white arrows. The
positions of cell nuclei were located by 4′,6-diamidino-2-phenylindole (DAPI)
staining, indicated in blue.
Additional file 4: Figure S2. Depletion of soluble CD18 (sCD18) by
binding to intercellular adhesion molecule 1 (ICAM-1) expressed on the
human umbelical vein cell line EA.hy926 or spondyloarthritis (SpA)
fibroblast-like synoviocytes (FLSs). Culture medium supplemented with
50% (vol/vol) normal human serum (NHS) or 50% (vol/vol) synovial fluid
mononuclear cell (SFMC) supernatant as sCD18 source were incubated
with EA.hy926 or SPA FLS cells, each cell type either cultured in the
supplemented media with 10 ng/mL tumor necrosis factor-alpha (TNFα)
(to induce ICAM-1 expression) or in the supplemented media without
further additions (“Medium”).
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